Country eligibility policy

in page functions

Gavi aims to focus its funding support on the world's poorest countries and has adopted a policy that is reflective of this. There are currently 49 Gavi eligible countries.

Eligibility for Gavi support is determined by national income with all countries with a Gross National Income (GNI) per capita below or equal to US$ 1,580 (according to World Bank data for the latest available year) qualifying for support.

Under the revised eligibility policy, there are currently 49 "Gavi-eligible" countries.

Download the policy

What is the purpose of Gavi's eligibility policy?

This policy sets out the revised eligibility criteria that Gavi uses since 2011 to determine which countries can apply for support at a specific point in time. The policy further outlines the programme filters which determine the requirements for accessing support for certain vaccines.

When is the policy applied and how does it work?

The eligibility policy is applied continuously to list countries that can apply for new Gavi support in any particular application round.

Gavi updates the eligibility threshold annually to take into account inflation adjustments, the latest World Bank GNI per capita figures and DTP3 coverage data released by the World Health Organization (WHO).

All countries with GNI per capita data equal or below the established threshold (currently US$ 1,580) are eligible to apply for new vaccine or cash-based programme support from Gavi. For Gavi new vaccines support, only countries with DTP3 coverage levels greater than or equal to 70%, based on the latest available WHO/UNICEF estimates, are eligible to apply. However, countries can apply for Inactivate Poliovirus (IPV), Meningitis A, Yellow fever, HPV demo and Measles-rubella vaccines irrespective of DTP3 coverage levels.

When was the current policy approved and when will it be updated?

The revised eligibility policy came into effect on 1 January 2011, following November 2009 Gavi Board approval. The eligibility threshold will be updated annually for inflation adjustments and to take into account newly released GNI per capita data.

More on this topic

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here